Isaac Zike, Ph.D. is a Managing Director at RiverVest Venture Partners, where he supports operational and development activities of current portfolio companies, manages diligence processes on potential new investments, and facilitates the development of novel opportunities.

It is a privilege to be part of such a strong and cohesive team that is committed to identifying impactful technologies and empowering entrepreneurs to develop therapies that dramatically improve patients’ lives.

Isaac Zike,



Isaac Zike, Ph.D. joined RiverVest in 2019 as a Senior Associate, was promoted to Principal in 2021, and to Managing Director in 2023. Isaac embodies a rare combination of scientific and investment expertise that adds depth and rigor to deal origination, due diligence, and portfolio company support. Drawing on his broad scientific expertise, as well as his analytical and product development strengths, Isaac has been instrumental in advancing several early-stage drug candidates during his tenure with RiverVest. 


Isaac serves as a director on the boards of SeQure Dx and a stealth biopharma company as well as a board observer for Glycomine, Sparrow Pharmaceuticals, and Wugen, all of which are RiverVest portfolio companies. He earned a B.S. from the University of Minnesota Twin Cities, double majoring in Biochemistry and in Genetics, Cell Biology, and Development. Following his undergraduate studies, he completed a Ph.D. in Pharmacology at Vanderbilt University, where he worked in the lab of Dr. Veenstra-VanderWeele, focusing his thesis work on the evaluation and validation of novel animal models for psychiatric disease.


Prior to joining RiverVest, Isaac worked as an associate within the Life Sciences practice at the Huron Consulting Group in New York City, where he assisted pharmaceutical and biotech clients on strategic projects ranging from early optimization of R&D processes to commercialization strategies for marketed products.


© Copyright RiverVest® All Rights Reserved.